Primary Cancer Clinical Trials

3 recruiting

Primary Cancer Trials at a Glance

7 actively recruiting trials for primary cancer are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Bellaire, Boston, and Caen. Lead sponsors running primary cancer studies include Cancer Council NSW, Centre Leon Berard, and Aura Biosciences.

Browse primary cancer trials by phase

Treatments under study

About Primary Cancer Clinical Trials

Looking for clinical trials for Primary Cancer? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Primary Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Primary Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)

Head and Neck CancerHead and Neck Squamous Cell CarcinomaUnknown Primary Cancer
University of Texas Southwestern Medical Center120 enrolled1 locationNCT05576974
Recruiting
Phase 2

Suprachoroidal Administration in Subjects With Metastases to the Choroid

Eye CancerPrimary Cancer
Aura Biosciences24 enrolled10 locationsNCT06643884
Recruiting
Not Applicable

COBRA: Cancer, Older Adults, Balance and Resistance Activities

CancerMetastatic CancerPrimary Cancer
Memorial Sloan Kettering Cancer Center38 enrolled6 locationsNCT07011862
Recruiting
Phase 2

PREventing Second Cancers With DOSTARlimab

Recurrent CancerSecond CancerPrimary Cancer
Centre Leon Berard400 enrolled5 locationsNCT05855811
Recruiting

AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer

Lung CancerLung MetastasesIndeterminate Pulmonary Nodules+1 more
Royal Marsden NHS Foundation Trust1,000 enrolled2 locationsNCT05375591
Recruiting

NSW Cancer Lifestyle and Evaluation of Risk Study (CLEAR Study)

Any primary cancer diagnosed in the past 18 months
Cancer Council NSW10,000 enrolled1 locationACTRN12611000678998
Recruiting

Utilization of 5HTT gene polymorphism as a prognostic indicator in cancer

cancer. We are recruiting patients with a known primary cancer of the following types: lymphoma, lung, gastrointestinal tumours, genitourinary tumours, hepatocellular cancer, breast, nasopharyngeal cancers). Adjustment for cancer type in the statisticall analysis will be done by including cancer type in the regression model.
University of Alexandria300 enrolled1 locationACTRN12610000028000